Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Friday, 15'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 13'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
02:21pm, Thursday, 07'th Aug 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Ka
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
11:10am, Thursday, 07'th Aug 2025
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
08:01pm, Wednesday, 06'th Aug 2025
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare t
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
07:40pm, Wednesday, 06'th Aug 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.56 per share a year ago.
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
04:13pm, Wednesday, 06'th Aug 2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
08:03am, Monday, 04'th Aug 2025
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Dire
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
10:41am, Friday, 01'st Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 30'th Jul 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Thursday, 24'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
11:36am, Wednesday, 23'rd Jul 2025
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
09:11am, Tuesday, 22'nd Jul 2025
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
